Seneca Therapeutics Receives FDA Clearance to Begin SVV-001 Phase I/II

 Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers announced today it had received FDA clearance to begin a Phase I/II clinical study utilizing Seneca Valley Virus (“SVV-001”) in combination with a checkpoint inhibitor. This Phase I/II study with SVV-001 is in patients that are TEM8 positive and SVV-001 permissive with neuroendocrine tumors or neuroendocrine carcinomas. The study should begin enrollment early in 2023.

https://www.biospace.com/article/releases/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study